Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort

Neurology

Volumn 78, Issue 22, 2012, Pages 1736-1742

  Trampe, A K ^a   Hemmelmann, C ^b   Stroet, A ^a   Haghikia, A ^a   Hellwig, K ^a   Wiendl, H ^c   Goelz, S ^d   Ziegler, A ^b   Gold, R ^a   Chan, A ^a  

^a ST JOSEF HOSPITAL   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c UNIVERSITY OF MÜNSTER   (Germany)

^d ELAN PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; NATALIZUMAB; VIRUS ANTIBODY;

ACCURACY; ADULT; ARTICLE; BLOOD SAMPLING; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GERMANY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; JC VIRUS; LEUKOENCEPHALOPATHY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; OPEN STUDY; POSTMARKETING SURVEILLANCE; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK; SEROLOGY;

EID: 84863607194     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182583022     Document Type: Article

References (14)

1. Clifford DB, De Luca A, Simpson DM, Arendt G, Giovannoni G, Nath A. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: Lessons from 28 cases. Lancet Neurol 2010;9: 438-446.
2. Hellwig K, Gold R. Progressive multifocal leukoencephalopathy and natalizumab. J Neurol 2011;258:1920-1928.
3. Vermersch P, Kappos L, Gold R, et al. Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology 2011;76:1697-1704.
4. Bozic C, Richman S, Plavina T, et al. Anti-John Cunningham virus antibody prevalence in multiple sclerosis patients: Baseline results of STRATIFY-1. Ann Neurol 2011; 70:713-721.
5. Goelz SE, Gorelik L, Subramanyam M. Assay design and sample collection can affect anti-John Cunningham virus antibody detection. Ann Neurol 2011;69:429-431.
6. Gorelik L, Lerner M, Bixler S, et al. Anti-JC virus antibodies: Implications for PML risk stratification. Ann Neurol 2010;68:295-303.
7. Rudick RA, O'Connor PW, Polman CH, et al. Assessment of JC virus DNA in blood and urine from natalizumabtreated patients. Ann Neurol 2010;68:304-310.
8. Flachenecker P, Stuke K, Elias W, et al. Multiple sclerosis registry in Germany: Results of the extension phase 2005/ 2006. Dtsch Arztebl Int 2008;105:113-119. (Pubitemid 351309708)
9. Sandrock A. Hotermans C, Richman S, et al. Risk stratification for progressive multifocal leukoencephalopathy (PML) in MS patients: Role of prior immunosuppressant use, natalizumab-treatment duration, and anti-JCV antibody status. Presented at the 63rd Annual Meeting of the American Academy of Neurology; April 9-16, 2011; Honululu, HI.
10. Sorensen PS, Jensen PE, Haghikia A, et al. Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab. Mult Scler 2011; 17:1074-1078.
11. Plavina T, Berman M, Njenga M, et al. Multi-site analytical validation of an assay to detect anti-JCV antibodies in human serum and plasma. J Clin Virol 2012;53:65-71.
12. Chan A, Weilbach FX, Toyka KV, Gold R. Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients. Clin Exp Immunol 2005;139: 152-158. (Pubitemid 40066141)
13. Hohlfeld R, Toyka KV, Besinger UA, Gerhold B, Heininger K. Myasthenia gravis: Reactivation of clinical disease and of autoimmune factors after discontinuation of longterm azathioprine. Ann Neurol 1985;17:238-242. (Pubitemid 15136597)
14. Haghikia A, Perrech M, Pula B, et al. Functional energetics of CD4+-cellular immunity in monoclonal antibodyassociated progressive multifocal leukoencephalopathy in autoimmune disorders. PloS One 2011;6:e18506.